Circulating Transforming Growth Factor Beta (TGF-β) in Individuals With Marfan Syndrome

Conditions

Marfan Syndrome

Keywords

TGF-B blood levels Atenolol vs, Losartan Study, NIH, NIHLB and NMF

Brief summary

Transforming Growth Factor Beta (TGF-β) is a protein that controls proliferation, cellular differentiation, and other functions in most cells. TGF-β levels play a major role in the pathogenesis of Marfan syndrome, a disease characterized by disproportionate height, long extremities, lens dislocation in the eyes and heart complications such as mitral valve prolapse and aortic enlargement increasing the likelihood of aortic dissection. While the underlying defect in Marfan syndrome is faulty synthesis of the glycoprotein fibrillin I, normally an important component of elastic fibers it has been shown that the Marfan syndrome phenotype can be relieved by addition of a TGF-β antagonist in affected mice.

Detailed description

Transforming Growth Factor Beta (TGF-β) is a protein that controls proliferation, cellular differentiation, and other functions in most cells. TGF-β levels play a major role in the pathogenesis of Marfan syndrome, a disease characterized by disproportionate height, long extremities, lens dislocation in the eyes and heart complications such as mitral valve prolapse and aortic enlargement increasing the likelihood of aortic dissection. While the underlying defect in Marfan syndrome is faulty synthesis of the glycoprotein fibrillin I, normally an important component of elastic fibers it has been shown that the Marfan syndrome phenotype can be relieved by addition of a TGF-β antagonist in affected mice. This suggest that while the symptoms of Marfan syndrome may seem consistent with a connective tissue disorder, the mechanism is more likely related to reduced sequestration of TGF-β by fibrillin.

Related papers

No related papers found yet.

Interventions

OTHERBlood draw

This study includes one blood draw to measure circulating blood levels of TGF-B.

Study design

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

6 Months to 24 Years

Healthy volunteers

No

Inclusion criteria

* Individual with Marfan syndrome consented in to the Main Atenolol Vs. Losartan NIH study.

Exclusion criteria

* Subjects in the main PHN Marfan trial who have not achieved the maintenance drug dosing or who have stopped taking study drug.

Design outcomes

Primary

Measure	Time frame
To determine if circulating levels of TGF-β correlate with treatment arms: Atenolol vs. Losartan.	1 year

Secondary

Measure	Time frame	Description
To determine if circulating levels of TGF-β correlate with clinical outcomes within a treatment group or independent treatment groups.	1 year	These clinical outcomes may be a change in aortic root Z-score, final aortic root dimension, final aortic root Z-score and other clinical outcomes in the main Marfan trial.

Countries

United States

Outcome results

None listed